Skip to content

System accuracy evaluation of up to 6 blood glucose monitoring systems based on ISO 15197:2013 / EN ISO 15197:2015

System accuracy evaluation of up to 6 blood glucose monitoring systems based on ISO 15197:2013 / EN ISO 15197:2015 - IfDT-2159-IU

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00026977
Enrollment
120
Registered
2021-10-29
Start date
2022-01-18
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E14

Interventions

Sponsors

Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm (IfDT)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Signed informed consent form - Subjects are legally competent and capable to understand character, meaning and consequences of the study. - If blood glucose values 300 mg/dl shall be measured after short term alteration in insulin therapy: - Male or female with type 1 diabetes and intensified insulin therapy or insulin pump therapy. - Signature of subjects to document consent with these procedures on informed consent form.

Exclusion criteria

Exclusion criteria: - Pregnancy or lactation period if venous samples are needed - Severe acute disease that compromises the subject’s capability to participate in the study (at the study physician’s discretion) - Severe chronic disease with potential risk during the test procedures (at the study physician’s discretion) - Medical relevant anemia - Suspected lack of compliance - Dependence on investigator or sponsor - If blood glucose values < 80 mg/dl shall be measured after short term alteration in insulin therapy: - Pregnancy or lactation period - Subjects with type 1 diabetes, suffering from - Coronary heart disease - Condition after myocardial infarction - Condition after cerebral events - Peripheral arterial occlusive disease - Hypoglycemia unawareness

Design outcomes

Primary

MeasureTime frame
Percentage of measurement results within ±15 mg/dl (für blood glucose concentrations <100 mg/dl) or within ±15% (=100 mg/dl) of comparison measurement results

Secondary

MeasureTime frame
Percentage of results within zones A and B of the Consensus Error Grid

Countries

Germany

Contacts

Public ContactStefan Pleus

Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm (IfDT)

stefan.pleus@idt-ulm.de0049 731 509 900

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026